Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $3.60, $0.11 better than the analyst estimate of $3.49. Revenue for the quarter came in at $2.2 billion versus the consensus estimate of $2.13 billion.

GUIDANCE:

Vertex Pharma raises FY2022 revenue to $8.6-8.8 billion, versus the consensus of $8.58 billion.

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.